No Data
No Data
IDT Australia Completes AU$7 Million 1-for-4.5 Entitlement Offer at AU$0.09 Per Share
IDT Australia (ASX:IDT) has completed its fully underwritten 1-for-4.5 entitlement offer of around AU$7 million, at AU$0.09 per share, according to a Wednesday Australian bourse filing.Shares in IDT
IDT Australia to Pioneer National ADC Manufacturing With Victorian Government Grant
Pharmaceutical manufacturing company IDT Australia (ASX: IDT) has been awarded a grant by the Victoria state government to partly fund the establishment of Australia’s first current good manufacturing practice antibody-drug-conjugate (ADC) manufacturing facility.
IDT Australia Secures Victorian Government Funding for Cancer Medication Production Facility
IDT Australia (ASX:IDT) secured AU$3.8 million in grant funding from the Victorian Industry Investment Fund to support the development of a manufacturing facility specializing in antibody-drug conjuga
IDT Australia Signs Master Service Agreement With Sanofi
IDT Australia (ASX:IDT) signed a master service agreement with Sanofi to support the Good Manufacturing Practice (cGMP) manufacture of the latter's messenger RNA assets under development, according to
Invion Nears Clinical Trial of Cancer Photodynamic Therapy With Drug Substance Production
Invion (ASX:IVX) said it made a significant step towards initiating the clinical trials of INV043 following the "successful" production of the said drug substance by partner IDT Australia (ASX:IDT). W
IDT Australia Raises AU$2 Million Via Share Purchase Plan
IDT Australia (ASX:IDT) raised AU$2 million via an oversubscribed share purchase plan of 30,769,354 shares at AU$0.065 apiece. Proceeds will be used to fund the pharmaceutical company's capital expend
No Data